HAIFA, Israel--(BUSINESS WIRE)--June 26, 2006--Pluristem Life Systems, Inc. (OTCBB:PLRS - News), a cell therapy company dedicated to the commercialization of stem cell products, announces it has engaged Biologics Consulting Group, Inc. to assist in the Company’s pursuit of FDA approval of PLX-1. Pluristem’s PLX-1 will enable umbilical cord blood to become an alternative to bone marrow transplant, eliminating the current bone marrow transplant search and match process.
